Fanpep Research Memo (9): In addition to expanding the pipeline of antibody-inducing peptides, the subsidiary is also developing non-pharmaceutical businesses.
■ Fan Pep <4881> will continue to expand its development pipeline focusing on diseases with high development significance among a wide range of chronic diseases, mainly in the "inflammation area" where antibody pharmaceuticals have already been launched, leveraging its unique technology of antibody-conjugated peptides. Since the target protein is the same as the antibody pharmaceuticals that are already on the market, the time needed to identify lead compounds can be significantly shortened, and safety and effectiveness have already been confirmed with antibody pharmaceuticals.
Takeda Commits Over $32M in Five New CSR Partnerships
Axcelead DDP and Lilly Enter Into Research and Collaboration Agreement
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
Today's flows: 09/17 SMC saw an inflow of JPY¥ 1.38 billion, Tokyo Electron saw an outflow of JPY¥ 6.74 billion
On September 17th, the TSE Main Market saw an inflow of JPY¥ 649.31 billion and an outflow of JPY¥ 690.51 billion.$SMC(6273.JP)$, $Mitsubishi Heavy Industries(7011.JP)$ and $Takeda Pharmaceutical(4502
Nikkei Average Contribution Ranking (Before Closing) - Nikkei Average plunged significantly, with Toshiba Electronic pushing down by about 144 yen in one stock.
As of the close on the 17th, the number of rising stocks in the Nikkei Average constituent stocks was 43, the number of declining stocks was 182, and the number of unchanged stocks was 0. The Nikkei Average continued to decline. Compared to the previous trading day, it finished the morning session at 35,828.54 yen (volume estimated at 900,100,000 shares) with a decrease of 753.22 yen (-2.06%). The US stock market on the 16th was mixed. The Dow Average closed at 41,622.08 yen, up 228.30 yen (+0.55%), and the Nasdaq was down 91.85 points (-0.52%) at 17.
Vatroslav Mateljic Appointed General Manager Of Takeda Canada
Express News | Vatroslav Mateljic Appointed General Manager of Takeda Canada
Press Release: Vatroslav Mateljic Appointed General Manager of Takeda Canada
The afternoon Nikkei average started 327 yen lower, with companies like Sakura and Tokyo Marine falling.
[Nikkei Average Stock Price / TOPIX (Table)] Nikkei Average; 36505.47; -327.80 TOPIX; 2568.13; -24.37 [Afternoon Opening Summary] The afternoon Nikkei average started at a similar level to the previous close (36507.10 yen) with a decline of 327.80 yen to 36505.47 yen. During the lunchtime, the Nikkei 225 futures traded in a range of 36230 yen to 36340 yen. The dollar-yen exchange rate was around 140.80-90 yen per dollar, about 50 yen higher than at 9 a.m.
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
The Nikkei average started 157 yen higher, with Nitori HD and Fujitsu rising.
[Nikkei Stock Average・TOPIX (Table)] Nikkei Average; 36,815.00; +157.91 TOPIX; 2619.04; -1.72 [Opening Summary] On the 6th, the Nikkei average started trading with a rebound of 157.91 yen to 36,815.00 yen, up 4 days. The U.S. stock market on the previous day, the 5th, was mixed. The Dow average ended trading at 40,755.75 dollars, down 219.22 dollars, and the Nasdaq closed at 17,127.66, up 43.36 points. The ADP employment statistics, which are private sector employment statistics, were released.
ADR Japanese stock ranking~ General buying dominance, Chicago is 40,000 yen higher than Osaka at 37,010 yen~
ADR (American Depositary Receipt) Japanese stocks, compared to the Tokyo Stock Exchange (converted at 1 dollar to 143.42 yen), Disco <6146>, Advantest <6857>, SMC <6273>, Tokyo Electron <8035>, HOYA <7741>, Renesas <6723>, Chugai Pharmaceutical <4519>, etc., are rising, with a general preference for buying. Chicago Nikkei 225 futures settlement price is 400 yen higher than Osaka daytime comparison at 37,010 yen. The US stock market is mixed. The Dow Jones Industrial Average is down 219.22 dollars to 40,755.75.
List of converted stocks (Part 2) [List of converted stocks for Parabolic Signal]
List of sell conversion stocks in the market Code Stock Name Closing Price SAR Tokushu-han <1301> Gyokuyo 3995 407
Regarding the release of "Seprorochin Injection 1000 units" (dried concentrated human protein C).
Regarding the release of "Sepurochin intravenous solution 1000 units" (dried concentrated human protein C) on September 6, 2024 - Congenital protein C deficiency is a rare condition that causes thrombosis due to the congenital deficiency of protein C, which has the function of suppressing blood clotting. It is indicated for the treatment of venous thromboembolism and disseminated intravascular coagulation caused by congenital protein C deficiency and for inhibiting thrombosis tendency. We provide a new treatment option for patients with congenital protein C deficiency. Today, our company has released the product "Sepu".
About manufacturing DX towards the realization of the Factory of the Future.
Announcements of individual stocks: Implementation of Manufacturing DX for the realization of Factory of the Future In September 5, 2024, we announced our efforts in Manufacturing Digital Transformation (DX) as part of the global program 'Factory of the Future', which strengthens the quality and stable supply of pharmaceuticals with AI and digital technologies, and achieved results at each manufacturing site.
Obtaining approval for the manufacturing and sale of the new coronavirus vaccine "Nubaksovid Muscle Injection 1mL" in response to the Omicron variant JN.1.
Announcements of individual stocks. On September 5, 2024, our company obtained manufacturing and sales approval for the new coronavirus vaccine "Nubakissovid Intramuscular Injection 1mL", which is compatible with the Omicron strain JN.1. We would like to inform you that we have obtained manufacturing and sales approval from the Ministry of Health, Labor and Welfare for the recombinant coronavirus (SARS-CoV-2) vaccine "Nubakissovid Intramuscular Injection 1mL", which was submitted for manufacturing and sales approval on April 12, 2024, as a prevention of infectious diseases caused by SARS-CoV-2.
Multiple Myeloma Market Report and Company Analysis, 2024-2032 Featuring Novartis, AbbVie., Sanofi, Johnson & Johnson, Baxter International, Pfizer, Takeda Pharmaceutical, and Bristol-Myers Squibb
CORUNDUM SYSTEMS BIOLOGY APPOINTS JESSICA SCHNEIDER AS CHIEF SCIENTIFIC OFFICER